[HTML][HTML] Pericytes in the tumor microenvironment

Z Jiang, J Zhou, L Li, S Liao, J He, S Zhou, Y Zhou - Cancer letters, 2023 - Elsevier
Pericytes are a type of mural cell located between the endothelial cells of capillaries and the
basement membrane, which function to regulate the capillary vasomotor and maintain …

Flavonoids as an effective sensitizer for anti-cancer therapy: Insights into multi-faceted mechanisms and applicability towards individualized patient profiles

A Liskova, M Samec, L Koklesova, A Brockmueller… - Epma Journal, 2021 - Springer
Cost-efficacy of currently applied treatments is an issue in overall cancer management
challenging healthcare and causing tremendous economic burden to societies around the …

Opportunities for small molecules in cancer immunotherapy

SY van der Zanden, JJ Luimstra, J Neefjes, J Borst… - Trends in …, 2020 - cell.com
Cancer immunotherapy has proven remarkably successful through instigation of systemic
antitumor T cell responses. Despite this achievement, further advancements are needed to …

Targeting transcription factor YY1 for cancer treatment: current strategies and future directions

R Hosea, S Hillary, S Wu, V Kasim - Cancers, 2023 - mdpi.com
Simple Summary Cancer is a global health problem with severe consequences. Certain
genes, known as transcription factors (TFs), are overactive in many tumors. Targeting these …

YY1 regulates cancer cell immune resistance by modulating PD-L1 expression

E Hays, B Bonavida - Drug Resistance Updates, 2019 - Elsevier
Recent advances in the treatment of various cancers have resulted in the adaptation of
several novel immunotherapeutic strategies. Notably, the recent intervention through …

[HTML][HTML] Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model

J Wu, X Zhao, Q Sun, Y Jiang, W Zhang, J Luo… - Biomedicine & …, 2020 - Elsevier
Background Immunotherapy has been shown to be effective as a first-line treatment option
for non-small cell lung cancer (NSCLC) patients. Unfortunately, it has failed to acquire an …

Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer

L Liu, M Mo, X Chen, D Chao, Y Zhang, X Chen… - Journal of Experimental …, 2023 - Springer
Background Lipid metabolic reprogramming in colon cancer shows a potential impact on
tumor immune microenvironment and is associated with response to immunotherapy …

Enhancement of tumour penetration by nanomedicines through strategies based on transport processes and barriers

H Yang, Z Tong, S Sun, Z Mao - Journal of Controlled Release, 2020 - Elsevier
Nanomedicines for antitumour therapy have been widely studied in recent decades, but only
a few have been used in clinical applications. One of the most important reasons is the poor …

The molecular mechanism of METTL3 promoting the malignant progression of lung cancer

C Ma, RJ Ma, K Hu, QM Zheng, YP Wang… - Cancer cell …, 2022 - Springer
Lung cancer remains one of the major causes of cancer-related death globally. Recent
studies have shown that aberrant m6A levels caused by METTL3 are involved in the …

Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell …

F Nichetti, F Ligorio, E Zattarin, D Signorelli, A Prelaj… - Cancers, 2019 - mdpi.com
PD-1 pathway blockade has been shown to promote proatherogenic T-cell responses and
destabilization of atherosclerotic plaques. Moreover, preclinical evidence suggests a …